Structural changes of the heart during severe sepsis or septic shock

Shock

Volumn 37, Issue 5, 2012, Pages 449-456

  Smeding, Lonneke ^a,b   Plötz, Frans B ^b,c   Groeneveld, A B Johan ^a,b,d   Kneyber, Martin C J ^a,b,e  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Department of Pediatrics   (Bulgaria)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Apoptosis; Edema; Heart failure; Inflammation; Mitochondria; Sepsis

Indexed keywords

CAFFEINE; CASPASE INHIBITOR; CYCLOSPORIN A; GLUTAMINE; SIMVASTATIN; THROMBOCYTE ACTIVATING FACTOR;

CELL DEATH; CELL INFILTRATION; EDEMA; ENDOTOXEMIA; HEART DISEASE; HEART FUNCTION; HUMAN; IMMUNOCOMPETENT CELL; NONHUMAN; REVIEW; SEPTIC SHOCK; SYSTEMATIC REVIEW;

EDEMA, CARDIAC; HUMANS; MITOCHONDRIA, HEART; MYOCARDIUM; SEPSIS; SHOCK, SEPTIC;

EID: 84859908124     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31824c3238     Document Type: Review

References (135)

1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655, 1992.
2. Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet 365:63-78, 2005.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310, 2001. (Pubitemid 32641789)
4. Court O, Kumar A, Parrillo JE, Kumar A: Clinical review: myocardial depression in sepsis and septic shock. Crit Care 6:500-508, 2002. (Pubitemid 35414581)
5. Etchecopar-Chevreuil C, Francois B, Clavel M, Pichon N, Gastinne H, Vignon P: Cardiac morphological and functional changes during early septic shock: a transesophageal echocardiographic study. Intensive Care Med 34:250-256, 2008.
6. Jardin F, Fourme T, Page B, Loubieres Y, Vieillard-Baron A, Beauchet A, Bourdarias JP: Persistent preload defect in severe sepsis despite fluid loading: a longitudinal echocardiographic study in patients with septic shock. Chest 116:1354-1359, 1999. (Pubitemid 29535992)
7. Vieillard-Baron A, Caille V, Charron C, Belliard G, Page B, Jardin F: Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med 36:1701-1706, 2008.
8. Charpentier J, Luyt CE, Fulla Y, Vinsonneau C, Cariou A, Grabar S, Dhainaut JF, Mira JP, Chiche JD: Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 32:660-665, 2004. (Pubitemid 38340060)
9. Poelaert J, Declerck C, Vogelaers D, Colardyn F, Visser CA: Left ventricular systolic and diastolic function in septic shock. Intensive Care Med 23:553-560, 1997. (Pubitemid 27263068)
10. Bouhemad B.Nicolas-Robin A, Arbelot C, Arthaud M, Feger F, Rouby J. J: Acute left ventricular dilatation and shock-induced myocardial dysfunction. Crit Care Med 37:441-447, 2009.
11. Munt B, Jue J, Gin K, Fenwick J, Tweeddale M: Diastolic filling in human severe sepsis: an echocardiographic study. Crit Care Med 26:1829-1833, 1998. (Pubitemid 28527694)
12. Jafri SM, Lavine S, Field BE, Bahorozian MT, Carlson RW: Left ventricular diastolic function in sepsis. Crit Care Med 18:709-714, 1990. (Pubitemid 20216234)
13. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE: Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 100:483-490, 1984. (Pubitemid 14126735)
14. Ellrodt AG, Riedinger MS, Kimchi A, Berman DS, Maddahi J, Swan HJ, Murata GH: Left ventricular performance in septic shock: reversible segmental and global abnormalities. Am Heart J 110:402-409, 1985. (Pubitemid 16054688)
15. Parker MM, McCarthy KE, Ognibene FP, Parrillo JE: Right ventricular dysfunction and dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humans. Chest 97:126-131, 1990. (Pubitemid 20023505)
16. Kimchi A, Ellrodt AG, Berman DS, Riedinger MS, Swan HJ, Murata GH: Right ventricular performance in septic shock: a combined radionuclide and hemodynamic study. J Am Coll Cardiol 4:945-951, 1984. (Pubitemid 15206643)
17. Chan CM, Klinger JR: The right ventricle in sepsis. Clin Chest Med 29:661-676, ix, 2008.
18. Rudiger A, Singer M: Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 35:1599-1608, 2007. (Pubitemid 46809326)
19. Merx MW, Weber C: Sepsis and the heart. Circulation 116:793-802, 2007. (Pubitemid 47255997)
20. Sharma AC: Sepsis-induced myocardial dysfunction. Shock 28:265-269, 2007. (Pubitemid 47282016)
21. Ammann P, Fehr T, Minder EI, Gunter C, Bertel O: Elevation of troponin I in sepsis and septic shock. Intensive Care Med 27:965-969, 2001. (Pubitemid 32662476)
22. Arlati S, Brenna S, Prencipe L, Marocchi A, Casella GP, Lanzani M, Gandini C: Myocardial necrosis in ICU patients with acute non-cardiac disease: a prospective study. Intensive Care Med 26:31-37, 2000. (Pubitemid 30184457)
23. Fenton KE, Sable CA, Bell MJ, Patel KM, Berger JT: Increases in serum levels of troponin I are associated with cardiac dysfunction and disease severity in pediatric patients with septic shock. Pediatr Crit Care Med 5:533-538, 2004.
24. Fernandes Junior CJ, Iervolino M, Neves RA, Sampaio EL, Knobel E: Interstitial myocarditis in sepsis. Am J Cardiol 74:958, 1994. (Pubitemid 24340326)
25. Maeder M, Fehr T, Rickli H, Ammann P: Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest 129:1349-1366, 2006.
26. Metha NJ, Khan IA, Gupta V, Jani K, Gowda RM, Smith PR: Cardiac troponin I predicts myocardial dysfunction and adverse outcome in septic shock. Int J Cardiol 95:13-17, 2004. (Pubitemid 38670466)
27. Rossi MA, Celes MR, Prado CM, Saggioro FP: Myocardial structural changes in long-term human severe sepsis/septic shock may be responsible for cardiac dysfunction. Shock 27:10-18, 2007. (Pubitemid 44968004)
28. Soriano FG, Nogueira AC, Caldini EG, Lins MH, Teixeira AC, Cappi SB, Lotufo PA, Bernik MM, Zsengeller Z, Chen M, et al.: Potential role of poly(adenosine 5¶-diphosphate-ribose) polymerase activation in the pathogenesis of myocardial contractile dysfunction associated with human septic shock. Crit Care Med 34:1073-1079, 2006.
29. Torgersen C, Moser P, Luckner G, Mayr V, Jochberger S, Hasibeder WR, Dunser MW: Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth Analg 108:1841-1847, 2009.
30. Turner A, Tsamitros M, Bellomo R: Myocardial cell injury in septic shock. Crit Care Med 27:1775-1780, 1999. (Pubitemid 29455103)
31. ver Elst KM, Spapen HD, Nguyen DN, Garbar C, Huyghens LP, Gorus FK: Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clin Chem 46:650-657, 2000. (Pubitemid 30318420)
32. Wu AH: Increased troponin in patients with sepsis and septic shock: myocardial necrosis or reversible myocardial depression? Intensive Care Med 27:959-961, 2001. (Pubitemid 32662474)
33. Desai SV, Law TJ, Needham DM: Long-term complications of critical care. Crit Care Med 39:371-379, 2011.
34. Wilcox ME, Herridge MS: Long-term outcomes in patients surviving acute respiratory distress syndrome. Semin Respir Crit Care Med 31:55-65, 2010.
35. Winters BD, Eberlein M, Leung J, Needham DM, Pronovost PJ, Sevransky JE: Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med 38:1276-1283, 2010.
36. Knoester H, Sol JJ, Ramsodit P, Kuipers IM, Clur SA, Bos AP: Cardiac function in pediatric septic shock survivors. Arch Pediatr Adolesc Med 162: 1164-1168, 2008.
37. Moon VH: The pathology of secondary shock. Am J Pathol 24:235-273, 1948.
38. Bronsveld W, van Lambalgen AA, van Velzen D, van den Bos GC, Koopman PA, Thijs LG: Myocardial metabolic and morphometric changes during canine endotoxin shock before and after glucose-insulin-potassium. Cardiovasc Res 19:455-464, 1985. (Pubitemid 16239455)
39. Yu P, Boughner DR, Sibbald WJ, keys J, Dunmore J, Martin CM: Myocardial collagen changes and edema in rats with hyperdynamic sepsis. Crit Care Med 25:657-662, 1997. (Pubitemid 27193980)
40. Gotloib L, Shostak A, Galdi P, Jaichenko J, Fudin R: Loss of microvascular negative charges accompanied by interstitial edema in septic rats' heart. Circ Shock 36:45-56, 1992.
41. Goddard CM, Allard MF, Hogg JC, Walley KR: Myocardial morphometric changes related to decreased contractility after endotoxin. Am J Physiol 270:H1446-H1452, 1996.
42. Solomon MA, Correa R, Alexander HR, Koev LA, Cobb JP, Kim DK, Roberts WC, Quezado ZM, Scholz TD, Cunnion RE, et al.: Myocardial energy metabolism and morphology in a canine model of sepsis. Am J Physiol 266:H757-H768, 1994.
43. Coalson JJ, Hinshaw LB, Guenter CA, Berrell EL, Greenfield LJ: Pathophysiologic responses of the subhuman primate in experimental septic shock. Lab Invest 32:561-569, 1975.
44. Hersch M, Gnidec AA, Bersten AD, Troster M, Rutledge FS, Sibbald WJ: Histologic and ultrastructural changes in nonpulmonary organs during early hyperdynamic sepsis. Surgery 107:397-410, 1990. (Pubitemid 20135397)
45. Schlag G, Redl H, van Vuuren CJ, Davies J: Hyperdynamic sepsis in baboons: II. Relation of organ damage to severity of sepsis evaluated by a newly developed morphological scoring system. Circ Shock 38:253-263, 1992.
46. Mela L, Hinshaw LB, Coalson JJ: Correlation of cardiac performance, ultrastructural morphology, and mitochondrial function in endotoxemia in the dog. Circ Shock 1:265-272, 1974.
47. Dongaonkar RM, Stewart RH, Geissler HJ, Laine GA: Myocardial microvascular permeability, interstitial oedema, and compromised cardiac function. Cardiovasc Res 87:331-339, 2010.
48. Yang LL, Gros R, Kabir MG, Sadi A, Gotlieb AI, Husain M, Stewart DJ: Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation 109:255-261, 2004. (Pubitemid 38114148)
49. Nemoto S, Vallejo JG, Knuefermann P, Misra A, Defreitas G, Carabello BA, et al.: Escherichia coli LPS-induced LV dysfunction: role of toll-like receptor-4 in the adult heart. Am J Physiol Heart Circ Physiol 282:H2316-H2323, 2002. (Pubitemid 34663043)
50. Tavener SA, Long EM, Robbins SM, McRae KM, Van Remmen H, Kubes P: Immune cell Toll-like receptor 4 is required for cardiac myocyte impairment during endotoxemia. Circ Res 95:700-707, 2004. (Pubitemid 39331930)
51. Zou L, Feng Y, Chen YJ, Si R, Shen S, Zhou Q, Ichinose F, Scherrer-Crosbie M, Chao W: Toll-like receptor 2 plays a critical role in cardiac dysfunction during polymicrobial sepsis. Crit Care Med 38:1335-1342, 2010.
52. Souza HP, Lima-Salgado T, da Cruz Neto LM: Toll-like receptors in sepsis: a tale still being told. Endocr Metab Immune Disord Drug Targets 10:285-291, 2010.
53. Shindo T, Kurihara H, Kurihara Y, Morita H, Yazaki Y: Upregulation of endothelin-1 and adrenomedullin gene expression in the mouse endotoxin shock model. J Cardiovasc Pharmacol 31(Suppl 1):S541-S544, 1998. (Pubitemid 128710006)
54. Schouten M, Wiersinga WJ, Levi M, van der Poll T: Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 83:536-545, 2008. (Pubitemid 351966862)
55. Raeburn CD, Calkins CM, Zimmerman MA, Song Y, Ao L, Banerjee A, Harken AH, Meng X: ICAM-1 and VCAM-1 mediate endotoxemic myocardial dysfunction independent of neutrophil accumulation. Am J Physiol Regul Integr Comp Physiol 283:R477-R486, 2002. (Pubitemid 34863896)
56. Massey KD, Strieter RM, Kunkel SL, Danforth JM, Standiford TJ: Cardiac myocytes release leukocyte-stimulating factors. Am J Physiol 269:H980-H987, 1995.
57. Kneyber MC, Gazendam RP, Niessen HW, Kuiper JW, dos Santos CC, Slutsky AS, Plotz FB: Mechanical ventilation during experimental sepsis increases deposition of advanced glycation end products and myocardial inflammation. Crit Care 13:R87, 2009.
58. Baidoshvili A, Krijnen PA, Kupreishvili K, Ciurana C, Bleeker W, Nijmeijer R, Visser CA, Visser FC, Meijer CJ, Stooker W, et al.: N(varepsilon)-(carboxymethyl) lysine depositions in intramyocardial blood vessels in human and rat acute myocardial infarction: a predictor or reflection of infarction? Arterioscler Thromb Vasc Biol 26:2497-2503, 2006. (Pubitemid 44607471)
59. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96:1395-1403, 1995.
60. Schmidt AM, Yan SD, Yan SF, Stern DM: The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 1498:99-111, 2000.
61. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D, Schmidt AM: Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 97:238-243, 1996.
62. Boldt J, PapsdorfM, Kumle B, Piper S, Hempelmann G: Influence of angiotensinconverting enzyme inhibitor enalaprilat on endothelial-derived substances in the critically ill. Crit Care Med 26:1663-1670, 1998. (Pubitemid 28467674)
63. Vanasco V, Cimolai MC, Evelson P, Alvarez S: The oxidative stress and the mitochondrial dysfunction caused by endotoxemia are prevented by alphalipoic acid. Free Radic Res 42:815-823, 2008.
64. Fauvel H, Marchetti P, Chopin C, Formstecher P, Neviere R: Differential effects of caspase inhibitors on endotoxin-induced myocardial dysfunction and heart apoptosis. Am J Physiol Heart Circ Physiol 280:H1608-H1614, 2001.
65. Neviere R, Fauvel H, Chopin C, Formstecher P, Marchetti P: Caspase inhibition prevents cardiac dysfunction and heart apoptosis in a rat model of sepsis. Am J Respir Crit Care Med 163:218-225, 2001. (Pubitemid 32095273)
66. Chagnon F, Bentourkia M, Lecomte R, Lessard M, Lesur O: Endotoxininduced heart dysfunction in rats: assessment of myocardial perfusion and permeability and the role of fluid resuscitation. Crit Care Med 34:127-133, 2006. (Pubitemid 43032389)
67. Zhou M, Wang P, Chaudry IH: Cardiac contractility and structure are not significantly compromised even during the late, hypodynamic stage of sepsis. Shock 9:352-358, 1998. (Pubitemid 128463884)
68. Piper RD, Li FY, Myers ML, Sibbald WJ: Structure-function relationships in the septic rat heart. Am J Respir Crit Care Med 156:1473-1482, 1997. (Pubitemid 27505512)
69. Iwase M, Yokota M, Kitaichi K, Wang L, Takagi K, Nagasaka T, Izawa H, Hasegawa T: Cardiac functional and structural alterations induced by endotoxin in rats: importance of platelet-activating factor. Crit Care Med 29:609-617, 2001. (Pubitemid 32225305)
70. Crouser ED: Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome. Mitochondrion 4:729-741, 2004. (Pubitemid 39646818)
71. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, Davies NA, Cooper CE, Singer M: Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 360:219-223, 2002. (Pubitemid 34804650)
72. Exline MC, Crouser ED: Mitochondrial mechanisms of sepsis-induced organ failure. Front Biosci 13:5030-5041, 2008. (Pubitemid 351599656)
73. Svistunenko DA, Davies N, Brealey D, Singer M, Cooper CE: Mitochondrial dysfunction in patients with severe sepsis: an EPR interrogation of individual respiratory chain components. Biochim Biophys Acta 1757:262-272, 2006.
74. Fauvel H, Marchetti P, Obert G, Joulain O, Chopin C, Formstecher P, Neviere R: Protective effects of cyclosporin A from endotoxin-induced myocardial dysfunction and apoptosis in rats. Am J Respir Crit Care Med 165:449-455, 2002. (Pubitemid 34165466)
75. Gellerich FN, Trumbeckaite S, Hertel K, Zierz S, Muller-Werdan U, Werdan K, Redl H, Schlag G: Impaired energy metabolism in hearts of septic baboons: diminished activities of complex I and complex II of the mitochondrial respiratory chain. Shock 11:336-341, 1999.
76. Hauptmann S, Klosterhalfen B, Weis J, Poche R, Mittermayer C, Kirkpatrick CJ: Morphology of cardiac muscle in septic shock. Observations with a porcine septic shock model. Virchows Arch 426:487-491, 1995.
77. Joshi MS, Julian MW, Huff JE, Bauer JA, Xia Y, Crouser ED: Calcineurin regulates myocardial function during acute endotoxemia. Am J Respir Crit Care Med 173:999-1007, 2006.
78. Larche J, Lancel S, Hassoun SM, Favory R, Decoster B, Marchetti P, Chopin C, Neviere R: Inhibition of mitochondrial permeability transition prevents sepsis-induced myocardial dysfunction and mortality. J Am Coll Cardiol 48:377-385, 2006.
79. Levy RJ, Vijayasarathy C, Raj NR, Avadhani NG, Deutschman CS: Competitive and noncompetitive inhibition of myocardial cytochrome c oxidase in sepsis. Shock 21:110-114, 2004.
80. McDonald TE, Grinman MN, Carthy CM, Walley KR: Endotoxin infusion in rats induces apoptotic and survival pathways in hearts. Am J Physiol Heart Circ Physiol 279:H2053-H2061, 2000.
81. Reed PC, Erve PR, Das Gupta TK, Schumer W: Endotoxemic effect of Escherichia coli on cardiac and skeletal muscle mitochondria. Surg Forum 21: 13-14, 1970.
82. Schumer W, Erve PR, Obernolte RP: Endotoxemic effect on cardiac and skeletal muscle mitochondria. Surg Gynecol Obstet 133:433-436, 1971.
83. Suliman HB, Welty-Wolf KE, Carraway M, Tatro L, Piantadosi CA: Lipopolysaccharide induces oxidative cardiac mitochondrial damage and biogenesis. Cardiovasc Res 64:279-288, 2004. (Pubitemid 39361689)
84. Trumbeckaite S, Opalka JR, Neuhof C, Zierz S, Gellerich FN: Different sensitivity of rabbit heart and skeletal muscle to endotoxin-induced impairment of mitochondrial function. Eur J Biochem 268:1422-1429, 2001. (Pubitemid 32231896)
85. Watts JA, Kline JA, Thornton LR, Grattan RM, Brar SS: Metabolic dysfunction and depletion of mitochondria in hearts of septic rats. J Mol Cell Cardiol 36:141-150, 2004. (Pubitemid 38084799)
86. Smeding L, van der Laarse WJ, van Veelen TA, Lamberts RR, Niessen HW, Kneyber MC, Johan Groeneveld AB, Plötz FB: Early myocardial dysfunction is not caused by mitochondrial abnormalities in a rat model of peritonitis. J Surg Res 2011 [e-pub ahead of print].
87. Tavener SA, Kubes P: Cellular and molecular mechanisms underlying LPS-associated myocyte impairment. Am J Physiol Heart Circ Physiol 290: H800-H806, 2006.
88. Sibelius U, Grandel U, Buerke M, Kiss L, Klingenberger P, Heep M, Bournelis E, Seeger W, Grimminger F: Leukotriene-mediated coronary vasoconstriction and loss of myocardial contractility evoked by low doses of Escherichia coli hemolysin in perfused rat hearts. Crit Care Med 31:683-688, 2003. (Pubitemid 36379568)
89. Grandel U, Bennemann U, Buerke M, Hattar K, Seeger W, Grimminger F, Sibelius U: Staphylococcus aureus alpha-toxin and Escherichia coli hemolysin impair cardiac regional perfusion and contractile function by activating myocardial eicosanoid metabolism in isolated rat hearts. Crit Care Med 37:2025-2032, 2009.
90. Hotchkiss RS, Rust RS, Dence CS, Wasserman TH, Song SK, Hwang DR, Karl IE, Welch MJ: Evaluation of the role of cellular hypoxia in sepsis by the hypoxic marker [18F]fluoromisonidazole. Am J Physiol 261:R965-R972, 1991.
91. Hotchkiss RS, Song SK, Neil JJ, Chen RD, Manchester JK, Karl IE, Lowry OH, Ackerman JJ: Sepsis does not impair tricarboxylic acid cycle in the heart. Am J Physiol 260:C50-C57, 1991.
92. Alders DJ, Groeneveld AB, Binsl TW, de Kanter FJ, van Beek JH: Endotoxemia decreases matching of regional blood flow and O2 delivery to O2 uptake in the porcine left ventricle. Am J Physiol Heart Circ Physiol 300:H1459-H1466, 2011.
93. Groeneveld AB, van Lambalgen AA, van den Bos GC, Bronsveld W, Nauta JJ, Thijs LG: Maldistribution of heterogeneous coronary blood flow during canine endotoxin shock. Cardiovasc Res 25:80-88, 1991.
94. Halestrap AP, Pasdois P: The role of the mitochondrial permeability transition pore in heart disease. Biochim Biophys Acta 1787:1402-1415, 2009.
95. Zang Q, Maass DL, Tsai SJ, Horton JW: Cardiac mitochondrial damage and inflammation responses in sepsis. Surg Infect (Larchmt) 8:41-54, 2007. (Pubitemid 46598294)
96. Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP, Nishimura Y, Crowe RA, Cascio WE, Bradham CA, Brenner DA, et al.: The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1366:177-196, 1998. (Pubitemid 28467031)
97. Pinheiro da Silva F, Nizet V: Cell death during sepsis: integration of disintegration in the inflammatory response to overwhelming infection. Apoptosis 14:509-521, 2009.
98. Gurusamy N, Das DK: Is autophagy a double-edged sword for the heart? Acta Physiol Hung 96:267-276, 2009.
99. Hsieh CH, Pai PY, Hsueh HW, Yuan SS, Hsieh YC: Complete induction of autophagy is essential for cardioprotection in sepsis. Ann Surg 253: 1190-1200, 2011.
100. Verma R, Huang Z, Deutschman CS, Levy RJ: Caffeine restores myocardial cytochrome oxidase activity and improves cardiac function during sepsis. Crit Care Med 37:1397-1402, 2009.
101. Groening P, Huang Z, La Gamma EF, Levy RJ: Glutamine restores myocardial cytochrome c oxidase activity and improves cardiac function during experimental sepsis. JPEN J Parenter Enteral Nutr 35:249-254, 2011.
102. Friberg H, Ferrand-Drake M, Bengtsson F, Halestrap AP, Wieloch T: Cyclosporin A, but not FK 506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death. J Neurosci 18:5151-5159, 1998. (Pubitemid 28311932)
103. Supinski GS, Murphy MP, Callahan LA: MitoQ administration prevents endotoxin-induced cardiac dysfunction. Am J Physiol Regul Integr Comp Physiol 297:R1095-R1102, 2009.
104. Lowes DA, Thottakam BM, Webster NR, Murphy MP, Galley HF: The mitochondria-targeted antioxidant MitoQ protects against organ damage in a lipopolysaccharide-peptidoglycan model of sepsis. Free Radic Biol Med 45: 1559-1565, 2008.
105. Smeding L, Poi HL, Hu P, Shan Y, Haitsma J, Horvath E, Furmli S, Masoom H, Kuiper JW, Slutsky AS, et al.: Salutary effect of Resveratrol on sepsisinduced myocardial depression. Crit Care Med. In press.
106. Reynolds CM, Suliman HB, Hollingsworth JW, Welty-Wolf KE, Carraway MS, Piantadosi CA: Nitric oxide synthase-2 induction optimizes cardiac mitochondrial biogenesis after endotoxemia. Free Radic Biol Med 46:564-572, 2009.
107. Carre JE, Orban JC, Re L, Felsmann K, Iffert W, Bauer M, Suliman HB, Piantadosi CA, Mayhew TM, Breen P, et al.: Survival in critical illness is associated with early activation of mitochondrial biogenesis. Am J Respir Crit Care Med 182:745-751, 2010.
108. Levy RJ, Piel DA, Acton PD, Zhou R, Ferrari VA, Karp JS, Deutschman CS: Evidence of myocardial hibernation in the septic heart. Crit Care Med 33:2752-2756, 2005. (Pubitemid 41816407)
109. Ren J, Ren BH, Sharma AC: Sepsis-induced depressed contractile function of isolated ventricular myocytes is due to altered calcium transient properties. Shock 18:285-288, 2002.
110. Dhainaut JF, Huyghebaert MF, Monsallier JF, Lefevre G, Dall'Ava-Santucci J, Brunet F, Villemant D, Carli A, Raichvarg D: Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation 75:533-541, 1987. (Pubitemid 17026042)
111. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE: Cell death. N Engl J Med 361:1570-1583, 2009.
112. Langenfeld JE, Machiedo GW, Lyons M, Rush BF Jr, Dikdan G, Lysz TW: Correlation between red blood cell deformability and changes in hemodynamic function. Surgery 116:859-867, 1994. (Pubitemid 24347195)
113. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, Buchman TG, Karl IE: Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 27:1230-1251, 1999. (Pubitemid 29379358)
114. Buerke U, Carter JM, Schlitt A, Russ M, Schmidt H, Sibelius U, Grandel U, Grimminger F, Seeger W, Mueller-Werdan U, et al.: Apoptosis contributes to septic cardiomyopathy and is improved by simvastatin therapy. Shock 29:497-503, 2008. (Pubitemid 351416804)
115. Carlson DL, Willis MS, White DJ, Horton JW, Giroir BP: Tumor necrosis factor-alpha-induced caspase activation mediates endotoxin-related cardiac dysfunction. Crit Care Med 33:1021-1028, 2005. (Pubitemid 40638175)
116. Chopra M, Sharma AC: Apoptotic cardiomyocyte hypertrophy during sepsis and septic shock results from prolonged exposure to endothelin precursor. Front Biosci 12:3052-3060, 2007.
117. Lancel S, Joulin O, Favory R, Goossens JF, Kluza J, Chopin C, Formstecher P, Marchetti P, Neviere R: Ventricular myocyte caspases are directly responsible for endotoxin-induced cardiac dysfunction. Circulation 111:2596-2604, 2005. (Pubitemid 40740858)
118. Ashkenazi A, Dixit VM: Death receptors: signaling and modulation. Science 281:1305-1308, 1998. (Pubitemid 28406815)
119. Giroir BP, Johnson JH, Brown T, Allen GL, Beutler B: The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest 90:693-698, 1992.
120. Horton JW, Maass D, White J, Sanders B: Nitric oxide modulation of TNFalphaYinduced cardiac contractile dysfunction is concentration dependent. Am J Physiol Heart Circ Physiol 278:H1955-H1965, 2000. (Pubitemid 30439209)
121. Zhang H, Tasaka S, Shiraishi Y, Fukunaga K, Yamada W, Seki H, Ogawa Y, Miyamoto K, Nakano Y, Hasegawa N, et al.: Role of soluble receptor for advanced glycation end products on endotoxin-induced lung injury. Am J Respir Crit Care Med 178:356-362, 2008.
122. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 348:138-150, 2003. (Pubitemid 36056721)
123. Muller-Werdan U, Engelmann H, Werdan K: Cardiodepression by tumor necrosis factor-alpha. Eur Cytokine Netw 9:689-691, 1998.
124. Hotchkiss RS, Swanson PE, Cobb JP, Jacobson A, Buchman TG, Karl IE: Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T-and B-cellYdeficient mice. Crit Care Med 25:1298-1307, 1997. (Pubitemid 27347292)
125. Gao CQ, Sawicki G, Suarez-Pinzon WL, Csont T, Wozniak M, Ferdinandy P, Schulz R: Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc Res 57:426-433, 2003. (Pubitemid 36144221)
126. Schultz MJ, van der Poll T: Animal and human models for sepsis. Ann Med 34:573-581, 2002. (Pubitemid 36113816)
127. Carlson D, Maass DL, White DJ, Tan J, Horton JW: Antioxidant vitamin therapy alters sepsis-related apoptotic myocardial activity and inflammatory responses. Am J Physiol Heart Circ Physiol 291:H2779-H2789, 2006. (Pubitemid 44904078)
128. PielDA, Gruber PJ, Weinheimer CJ, Courtois MR, Robertson CM, Coopersmith CM, Deutschman CS, Levy RJ: Mitochondrial resuscitation with exogenous cytochrome c in the septic heart. Crit Care Med 35:2120-2127, 2007. (Pubitemid 47326449)
129. Liappis AP, Kan VL, Rochester CG, Simon GL: The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33:1352-1357, 2001. (Pubitemid 32955186)
130. Merx MW, Liehn EA, Janssens U, Lutticken R, Schrader J, Hanrath P, Weber C: HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 109:2560-2565, 2004. (Pubitemid 38720557)
131. Merx MW, Liehn EA, Graf J, van de SA, Schaltenbrand M, Schrader J, Hanrath P, Weber C: Statin treatment after onset of sepsis in a murine model improves survival. Circulation 112:117-124, 2005. (Pubitemid 40962577)
132. Janda S, Young A, Fitzgerald JM, Etminan M, Swiston J: The effect of statins on mortality from severe infections and sepsis: a systematic review and metaanalysis. J Crit Care 25:656.e7-656.e22, 2010.
133. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, Ibrahim T: Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 169:1658-1667, 2009.
134. Yende S, Milbrandt EB, Kellum JA, Kong L, Delude RL, Weissfeld LA, Angus DC: Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med 39:1871-1878, 2011.
135. Martin CP, Talbert RL, Burgess DS, Peters JI: Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation. Pharmacotherapy 27:20-26, 2007. (Pubitemid 46067959)